Search

Your search keyword '"Sevelda P"' showing total 570 results

Search Constraints

Start Over You searched for: Author "Sevelda P" Remove constraint Author: "Sevelda P"
570 results on '"Sevelda P"'

Search Results

2. Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34

4. IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes

8. Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition: Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology

18. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

19. Body image and self-esteem in lower-limb amputees.

27. Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial

33. 812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial

35. Lupus, das Chamäleon

38. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

39. Freie mitteilungen

45. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

47. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study

48. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment

49. Stereocontrolled Synthesis of Pseurotin A2

50. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years

Catalog

Books, media, physical & digital resources